Menu
/REGISTER
Montecito
Nixon Peabody
Loading...
You are here:  Home  >  Biotech

Montecito Bank & Trust
Latest

Amgen beats expectations in Q3 earnings report

By   /  Wednesday, October 28th, 2020  /  Banking & Finance, Biotech, Earnings, East Ventura County, Latest news, Tri-County Economy, Tri-County Public Companies  /  No Comments

Amgen, one of the biggest biopharmaceutical companies in the world, continued to see growth in the third quarter of 2020, despite the COVID-19 pandemic. The Thousand Oaks-based company saw total revenue of $6.4 billion for the quarter, up 12 percent from the third quarter of 2019. Earnings per share increased 5 percent to $3.43. Both Read More →

Read More →
Latest

Arcutis shares up on news of public, private offerings

By   /  Tuesday, September 29th, 2020  /  Banking & Finance, Biotech, Central Coast Health Watch, East Ventura County, Latest news, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Arcutis shares up on news of public, private offerings

Arcutis Biotherapeutics saw a 15 percent rise in its share price after it said Sept. 29 that it will offer 4 million shares to the public and sell another $35 million in stock to an affiliate of one of its directors. Arcutis closed at $31.04, a gain of $4.28 after it announced the dual track Read More →

Read More →
Latest

Amgen to team with Eli Lilly on COVID treatment

By   /  Friday, September 18th, 2020  /  Banking & Finance, Biotech, Central Coast Health Watch, East Ventura County, Latest news, Technology, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen to team with Eli Lilly on COVID treatment

Thousand Oaks biotech giant Amgen announced another strategy to help address the coronavirus pandemic, entering into a manufacturing agreement with Eli Lilly to produce COVID-19 antibodies.  Eli Lilly, based in Indianapolis, has been pursuing several antibody treatments for the virus, the two companies said in a Sept. 17 news release. With access to Amgen’s manufacturing Read More →

Read More →
Latest

Making an ImmPACT: New firm raises $18M to pursue T-cell therapies

By   /  Friday, August 28th, 2020  /  Biotech, Latest news  /  Comments Off on Making an ImmPACT: New firm raises $18M to pursue T-cell therapies

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen to join exclusive Dow Jones club

By   /  Monday, August 24th, 2020  /  Banking & Finance, Biotech, East Ventura County, Latest news, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen to join exclusive Dow Jones club

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen teams up with competitors in COVID treatment trial

By   /  Monday, August 3rd, 2020  /  Biotech, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Amgen teams up with competitors in COVID treatment trial

Amgen has joined two of its competitors in launching a trial for drugs to treat patients with COVID-19. Together with Chicago-based AbbVie and Japanese drugmaker Takeda Pharmaceutical, the Thousand Oaks biotech giant said Aug. 3 it had enrolled the first patients into a clinical trial for the anti-inflammatory drugs Otezla, cenicriviroc and Firazyr. Otezla is Read More →

Read More →
Latest

Amgen meets analyst estimates, but shares drop on Q2 earnings decline

By   /  Tuesday, July 28th, 2020  /  Banking & Finance, Biotech, Earnings, East Ventura County, Latest news, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen meets analyst estimates, but shares drop on Q2 earnings decline

Amgen’s revenues climbed 6 percent in the second quarter, to $6.2 billion, despite the COVID-19 pandemic limiting hospital and physician operations and putting a hitch in diagnosis and treatment for many patients. Amgen’s earnings, announced July 28, met average analyst estimates. However, a 17 percent overall decline in net income for the Thousand Oaks biotech Read More →

Read More →